articleNew England Journal of MedicineJun 12, 2019BRONZE OA

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

NRG Oncology · University of Kentucky · +13 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Background

Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence.

Methods

In this randomized phase 3 trial, we tested whether 6 months of platinum-based chemotherapy plus radiation therapy (chemoradiotherapy) is associated with longer relapse-free survival (primary end point) than six cycles of combination chemotherapy alone in patients with stage III or IVA endometrial carcinoma. Secondary end points included overall survival, acute and chronic toxic effects, and quality of life.

Citation impact

462
total citations
FWCI
46.83
Percentile
100%
References
37
Citations per year

Authors

18

Topics & keywords

Keywords
  • Endometrial cancer
  • Adjuvant
  • Medicine
  • Oncology
  • Internal medicine
  • Radiation therapy
  • Chemotherapy
  • Cancer
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding